Daily Respiratory Research Analysis
Three impactful respiratory studies stood out: a phase 3 perioperative immunotherapy trial in resectable NSCLC showed no detriment to surgery with added durvalumab; a systematic review supports FAPI radiotracers as promising activity biomarkers in interstitial lung diseases; and global genomics of H3 avian influenza reveal accelerated evolution after transmission to poultry, underscoring zoonotic risk.
Summary
Three impactful respiratory studies stood out: a phase 3 perioperative immunotherapy trial in resectable NSCLC showed no detriment to surgery with added durvalumab; a systematic review supports FAPI radiotracers as promising activity biomarkers in interstitial lung diseases; and global genomics of H3 avian influenza reveal accelerated evolution after transmission to poultry, underscoring zoonotic risk.
Research Themes
- Perioperative immuno-oncology in lung cancer
- Molecular imaging biomarkers for fibrosing interstitial lung diseases
- Viral evolution and zoonotic risk in respiratory pathogens
Selected Articles
1. Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC.
In the AEGEAN phase 3 trial, adding durvalumab to neoadjuvant chemotherapy did not impair surgical feasibility or timing and showed numerically higher R0 resection rates and nodal downstaging versus chemotherapy alone, with similar complication profiles. Median time from last neoadjuvant dose to surgery was 34 days in both arms.
Impact: These data address a critical practical question for perioperative immunotherapy in resectable NSCLC—whether it compromises surgery—supporting integration into multidisciplinary care.
Clinical Implications: Thoracic teams can proceed with standard surgical approaches and timelines when using durvalumab plus neoadjuvant chemotherapy, anticipating at least similar complication rates and potentially higher R0 and nodal downstaging.
Key Findings
- Surgery performed in 80.6% vs 80.7% and completed in 77.6% vs 76.7% (durvalumab vs placebo).
- Median time from last neoadjuvant dose to surgery was 34 days in both arms; surgery delays occurred in 17.3% vs 22.2%.
- R0 resection rate was higher with durvalumab (94.7% vs 91.3%); surgical complications were similar (59.1% vs 60.1%, mostly grade 1–2).
- Exploratory analyses showed greater nodal downstaging to N0 in durvalumab arm (N2→N0: 47.3% vs 40.2%; N1→N0: 53.6% vs 46.2%).
Methodological Strengths
- Randomized, double-blind, phase 3 design with global enrollment and standardized perioperative regimens.
- Large mITT population (n≈740) with detailed surgical metrics and safety reporting.
Limitations
- Surgical outcomes were descriptive and not primary endpoints; not powered for between-arm statistical testing of surgical metrics.
- Exclusion of EGFR/ALK-altered tumors in mITT may limit generalizability to all resectable NSCLC.
Future Directions: Prospective analyses linking surgical outcomes with long-term survival, perioperative biomarker studies, and subgroup assessments (e.g., by PD-L1, nodal stage) to refine patient selection.
INTRODUCTION: In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival (p = 0.004) and pathologic complete response (p < 0.001; primary end points; modified intention-to-treat [mITT] population, which excluded patients with known EGFR or ALK aberrations) with a manageable safety profile in patients with resectable (R)-NSCLC. Here, we report surgical outcomes from AEGEAN. METHODS: Patients with treatment-naive R-NSCLC (stage II-IIIB [N2]) and Eastern Cooperative Oncology Group performance status 0 or 1 were randomized (1:1) to platinum-based chemotherapy plus durvalumab or placebo intravenously (every 3 wk, 4 cycles) before surgery, followed by durvalumab or placebo (every 4 wk, 12 cycles). Surgical outcomes were summarized for the mITT population using descriptive statistics. RESULTS: A total of 737 out of 740 mITT patients received treatment, 366 and 371 in the durvalumab and placebo arms, respectively; 80.6% and 80.7% underwent surgery, 77.6% and 76.7% completed surgery, and of the 295 and 302 patients who underwent surgery, 17.3% and 22.2% had delayed surgery. The median time from last neoadjuvant dose to surgery was 34.0 days in both arms. Of the patients who underwent surgery, similar proportions had open (49.2% versus 50.7%) and minimally invasive (49.2% versus 47.0%) procedures; lobectomy was the most common procedure (88.1% versus 85.4%). R0 resection rates were numerically higher in the durvalumab versus placebo arm (94.7% versus 91.3%). The median time from surgery to first adjuvant dose was 50.0 versus 52.0 days. In exploratory analyses, a numerically higher proportion of patients in the durvalumab versus placebo arm with baseline N2 nodal status had downstaging from N2 to N0 (47.3% versus 40.2%) or, with baseline N1 nodal status, from N1 to N0 (53.6% versus 46.2%) after surgery. Similar proportions had surgical complication(s) (59.1% versus 60.1%), primarily grade 1 or 2 (53.0% versus 51.8%, modified safety analysis set). CONCLUSION: The addition of durvalumab to neoadjuvant chemotherapy had no detrimental effect on the feasibility, approach, type, or timing of surgery and was associated with a tolerable surgical safety profile, versus neoadjuvant chemotherapy alone. CLINICAL TRIAL INFORMATION: ClinicalTrials.Gov Identifier: NCT03800134.
2. Radio-labelled fibroblast activation protein inhibitors in interstitial lung diseases - a systematic review.
Across 13 studies, FAPI tracer uptake mapped to fibrotic lesions, correlated with PFTs and HRCT extent, and predicted progression; in animal models, uptake aligned with FAP-α expression and even preceded CT-detectable fibrosis. These findings position FAPI-PET as a candidate activity biomarker in ILD.
Impact: This review consolidates multi-system evidence that FAPI imaging captures active fibrogenesis and may enable earlier identification of progressive ILD, a key unmet need beyond structural imaging.
Clinical Implications: FAPI-PET could complement HRCT and PFTs for risk stratification and timing of antifibrotics in progressive fibrosing ILDs, potentially reducing diagnostic delays and enabling response-adaptive management.
Key Findings
- FAPI uptake was consistently elevated in ILD versus controls and localized to HRCT-defined fibrotic lesions.
- In murine models, uptake correlated with fibrosis and FAP-α expression, rose before CT-visible fibrosis, and attenuated once fibrosis established.
- In human ILD (IPF n=55, CTD-ILD n=68, other ILDs n=55), FAPI uptake correlated with baseline PFTs and HRCT fibrosis extent and predicted disease progression.
- Ex vivo analyses linked FAPI signal with increased FAP-α expression in fibrotic lung tissue.
Methodological Strengths
- Systematic search across major databases with inclusion of both preclinical and clinical studies, enabling triangulation.
- Consistent associations across imaging, physiology, histology, and outcomes.
Limitations
- Heterogeneity of tracers, imaging protocols, and patient populations; small cohorts limit generalizability.
- Lack of standardized thresholds and limited prospective validation; not a meta-analysis with pooled effect sizes.
Future Directions: Standardize acquisition/quantification, conduct prospective multicenter studies to validate prognostic thresholds, and test FAPI-guided treatment algorithms and response monitoring.
BACKGROUND: Currently, no tools can monitor ongoing fibrotic activity properly, making early identification of and timely therapeutic intervention with antifibrotics in patients with progressive fibrosing interstitial lung disease (ILD) difficult. Fibroblast activation protein-α inhibitor (FAPI) radiotracers could address these challenges. OBJECTIVE: This review examines the association between pulmonary FAPI tracer uptake, fibrotic activity, and clinical parameters used for disease monitoring and prognostication in ILD to provide insights into its clinical potential. METHODS: In January 2025, a systematic literature search on PubMed, Ovid Medline, and Cochrane Library, utilizing the block-search strategy and snowballing, was conducted, and 13 studies were included. RESULTS: Both murine and human studies support that FAPI tracer uptake reflects fibrotic activity in ILDs, as uptake was consistently elevated in subject groups compared to controls. In murine ILD models, increased uptake was associated with fibrosis and fibroblast activation protein-α (FAP-α) expression upon histological examination. Uptake preceded the development of fibrosis on computed tomography (CT) and attenuated once fibrosis was established. In human ILD patients (Idiopathic pulmonary fibrosis (IPF) = 55, Connective tissue disease (CTD) ILD = 68, other ILDs = 55), FAPI uptake was localized to fibrotic lesions on high-resolution computed tomography (HRCT) and associated with increased FAP-α expression ex vivo. Uptake correlated with baseline pulmonary function tests (PFTs) and fibrosis extent on HRCT. Increased FAPI tracer uptake at baseline predicted disease progression upon follow-up. CONCLUSION: An increasing body of evidence supports that FAPI tracers hold great clinical potential for the management of ILD by accurately monitoring fibrotic disease activity and identifying patients at risk of progression. Further research is required to confirm these findings.
3. Global spread of H3 subtype avian influenza viruses with an accelerated evolution after interspecies transmission.
Integrating public and surveillance datasets, the authors show that H3 AIV sublineages circulate globally across ≥90 bird species, with key dissemination hubs identified. After introduction into domestic poultry, HA substitution rates accelerate—fastest in chickens—consistent with shorter generation times and host selection; H3N8 G25 has spilled over to humans.
Impact: This work clarifies host-driven evolutionary acceleration of H3 AIVs in poultry and highlights human spillover, informing surveillance priorities and vaccine strain selection.
Clinical Implications: Enhanced surveillance in domestic chickens and high-traffic hubs, and proactive antigenic monitoring, may mitigate zoonotic spillover and improve preparedness for influenza with respiratory pandemic potential.
Key Findings
- H3 AIV sublineages detected worldwide across at least 90 bird species with key dissemination regions (e.g., Alaska, Central Asia, Chinese provinces).
- HA gene substitution rates increase after introduction from wild birds to domestic poultry, with the fastest rates in domestic chickens.
- Findings suggest shorter generation times and host selection drive accelerated evolution; novel chicken H3N8 G25 has spilled over to humans.
Methodological Strengths
- Combined public sequence databases with active surveillance data to map ecology, evolution, and spread.
- Comparative rate analyses highlighting host-specific acceleration of HA substitution.
Limitations
- Potential sampling and reporting biases in global sequence databases and regional surveillance.
- Observational phylogenetic analyses infer mechanisms but lack experimental validation of host selection pressures.
Future Directions: Link evolutionary rate changes to antigenic drift via phenotypic assays, expand poultry-focused longitudinal sampling, and assess human serologic cross-reactivity to emergent H3 lineages.
The H3 subtype avian influenza virus (AIV) has been widely spread in birds and is known as a natural source of mammalian influenza viruses. Based on data from public databases and our surveillance data, we analyzed the ecology, evolution, and spread of H3 AIVs. Sublineages of H3 AIVs have been detected worldwide, infecting various birds, at least 90 species in wild birds and poultry. Important areas for large-scale and local dissemination of H3 AIVs were identified, such as Alaska, Central Asia, and Chinese provinces. The H3 viruses have elevated the HA gene substitution rate after introduction from wild birds to domestic poultry, and even faster in domestic chickens. Our results implied an evolutionary mechanism of H3 AIV cross-species transmission, that viruses from wild birds to domestic poultry have accelerated substitution rate by shorter generation time and host selection. Novel chicken H3 viruses, especially H3N8 G25 viruses that have spilled over to humans, require high attention.